Quarterly updateArmata Pharmaceuticals, Inc.Armata reports new FDA milestones for AP-SA02 ahead of planned Phase 3 startArmata Pharmaceuticals disclosed Fast Track designation and an agreed pediatric study plan for AP-SA02 while confirming plans to begin a pivotal Phase 3 trial in the second half of 2026.SEC filing
Clinical readoutArmata Pharmaceuticals, Inc.Armata reports FDA submissions complete ahead of AP-SA02 Phase 3The company said it has submitted all requested clinical, CMC, and regulatory responses to the FDA following its End-of-Phase 2 meeting for AP-SA02.SEC filing
PeopleArmata Pharmaceuticals, Inc.Armata Pharmaceuticals names David House chief financial officerThe company elevated House from senior finance officer to CFO effective July 17, 2026, under a new employment agreement filed with the SEC.SEC filing
